Foghorn Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$50M
Industry:Biotech
Founded:2016
Lead Investor(s):Flagship Pioneering
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Foghorn Therapeutics's estimated annual revenue is currently $14.4M per year.
  • Foghorn Therapeutics received $50.0M in venture funding in March 2018.
  • Foghorn Therapeutics's estimated revenue per employee is $155,000
  • Foghorn Therapeutics's total funding is $50M.

Employee Data

  • Foghorn Therapeutics has 93 Employees.
  • Foghorn Therapeutics grew their employee count by 12% last year.
  • Foghorn Therapeutics currently has 6 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$8.7M5660%N/A
Tango Therapeut...
$12.9M8338%N/A
Compass Therape...
$16.4M10614%N/A
Cell Signaling ...
$89.4M577N/AN/A
Momenta Pharmac...
N/A220N/AN/A
Emulate
$15.3M99-17%N/A
ArQule
N/A94N/AN/A
Hamilton Storag...
$17.2M1119%N/A
Alnylam Pharmac...
$74.9M127731%N/A
Transgenomic
N/A47N/AN/A
Missing a competitor? Contribute!?
Submit

More than 20,000 genes make us human. Genes control critical aspects of health and disease but what controls our genes A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control(TM) platform, Foghorn will change how genes turn on and off. Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for usand rewrite destiny for millions of people living with disease. With Gene Traffic Control(TM) Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

keywords:N/A

93

Number of Employees

$14.4M

Revenue (est)

6

Current Jobs

12%

Employee Growth %

$50M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Jason LowePrincipal ScientistEmail Available
Lan XuDirector, BiologyEmail Available
Janice LeePrincipal Scientist
Jeremy SetserPrincipal ScientistEmail Available
Richard CentorePrincipal ScientistEmail Available
Steven BellonSVP Drug DiscoveryEmail Available
Joe MarchionnaDirector of Research Informatics
Rishi VaswaniPrincipal Scientist
Paul AllowayVice President & Head of Legal
Erin AdamsExecutive Assistant to Chief Scientific Officer

Foghorn Therapeutics News

09/08/2019 - Cigall Kadoch Unravels Chromatin’s Role in Cancer

Over the past few years, she has turned down money from pharmaceutical companies so that she could cofound Foghorn Therapeutics, hoping ...

05/12/2019 - Foghorn Therapeutics takes aim at chromatin hijackers to stop ...

A decade ago, when Cigall Kadoch joined Gerald Crabtree's lab at Stanford University, she was an odd fit: the incoming graduate student was ...

12/13/2018 - Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on ...

Foghorn Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-03-14$50.0MUndisclosedFlagship PioneeringArticle

Foghorn Therapeutics Executive Hires

DateNameTitleReference
2018-12-14Carl DeciccoChief Scientific OfficerArticle